Tesamorelin: Clinical Guide for Prescribing Practices
Tesamorelin is a growth hormone releasing hormone (GHRH) analog that stimulates pituitary GH secretion. It is FDA-approved (as Egrifta) for HIV-associated lipodystrophy and is widely compounded for body composition optimization, visceral fat reduction, and anti-aging protocols in clinical practice.
Also Known As
How Tesamorelin Works
Tesamorelin is a synthetic analog of human GHRH (amino acids 1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances stability and bioavailability [5]. It binds the pituitary GHRH receptor, stimulating cAMP-mediated GH synthesis and pulsatile secretion. The intact 44-amino-acid sequence provides full GHRH receptor activation with preserved somatostatin feedback, preventing supraphysiologic GH levels while effectively reducing visceral adipose tissue through GH-mediated lipolysis [2].
Clinical Evidence
Two pivotal Phase III trials (n=816 combined) demonstrated that tesamorelin 2mg daily significantly reduced visceral adipose tissue by 15 to 18% versus placebo over 26 weeks in HIV-associated lipodystrophy, leading to FDA approval of Egrifta in 2010 [1][2]. Subsequent studies showed improvements in trunk fat, triglycerides, and non-alcoholic fatty liver disease [3]. Emerging research in non-HIV populations suggests benefits for cognitive function in mild cognitive impairment [4] and metabolic health. IGF-1 normalization occurs predictably with standard dosing [5].
Clinical Uses
Patient Selection and Screening
FDA-approved indication is HIV-associated lipodystrophy with excess visceral adipose tissue [1]. Off-label candidates include patients with significant visceral adiposity, metabolic syndrome with central obesity, or those seeking GH optimization with the strongest evidence base [2]. Screen with baseline CT or DEXA for visceral fat quantification, IGF-1, fasting glucose, HbA1c, and lipid panel [5]. Contraindications include active malignancy, disruption of the hypothalamic-pituitary axis (surgery, radiation, trauma), and hypersensitivity to tesamorelin or mannitol.
Dosing and Administration
The FDA-approved dose is 2mg subcutaneously once daily, injected into the abdomen [5]. Clinical effect on visceral fat is typically assessed at 12 to 14 weeks; discontinue if no meaningful reduction is observed [2]. For off-label use in body composition optimization, the same 2mg daily dose is standard. Some protocols use 1mg daily as an initial titration for 1 to 2 weeks. No dose adjustment is required for renal or hepatic impairment. Monitor IGF-1 at baseline, week 6, and quarterly; discontinue if IGF-1 exceeds 3 times the upper limit of normal [5]. Treatment duration in clinical trials was 26 to 52 weeks [2]. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via daily subcutaneous injection, typically 2mg daily. Often prescribed as a standalone or in combination with other GH secretagogues.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Tesamorelin commands premium pricing due to its FDA-approved status and strong clinical evidence [1]. Brand Egrifta SV carries a list price of approximately $800 to $1,000 per month [5]. Compounded tesamorelin is available at significantly lower wholesale cost ($60 to $120 per vial for a 4-week supply), allowing practices to price programs at $350 to $700 per month with strong margins. The FDA approval history provides a significant differentiator for marketing and patient confidence compared to non-approved peptides.
FDA Category Status
FDA-approved (Egrifta) for HIV-lipodystrophy; compounded versions for off-label use require clinical justification
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Tesamorelin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the advantage of tesamorelin over direct GH administration?
How does tesamorelin compare to CJC-1295/Ipamorelin?
What monitoring is required for patients on tesamorelin?
References
- FDA Approval Letter: Egrifta (tesamorelin) for injection, 2010
- Falutz J et al. Effects of tesamorelin on visceral fat in HIV-infected patients. N Engl J Med. 2007;357(23):2359-2370
- Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease. Gut. 2014;63(11):1843-1849
- Bhatt RS et al. Growth hormone-releasing hormone analog improves cognition. Arch Neurol. 2012;69(11):1420-1429
- Egrifta SV (tesamorelin) Prescribing Information. Theratechnologies Inc.
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Tesamorelin Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Tesamorelin Through Karpa